

Trisomy 21 consistently activates the interferon response

ELife

5,

DOI: [10.7554/elife.16220](https://doi.org/10.7554/elife.16220)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Multivalent Chromatin Engagement and Inter-domain Crosstalk Regulate MORC3 ATPase. Cell Reports, 2016, 16, 3195-3207.	6.4	40
2	What people with Down Syndrome can teach us about cardiopulmonary disease. European Respiratory Review, 2017, 26, 160098.	7.1	73
3	Chromosome Mis-segregation Generates Cell-Cycle-Arrested Cells with Complex Karyotypes that Are Eliminated by the Immune System. Developmental Cell, 2017, 41, 638-651.e5.	7.0	263
4	Down syndrome and the complexity of genome dosage imbalance. Nature Reviews Genetics, 2017, 18, 147-163.	16.3	234
5	Systematic proteome and proteostasis profiling in human Trisomy 21 fibroblast cells. Nature Communications, 2017, 8, 1212.	12.8	112
6	Self-Organized Cerebral Organoids with Human-Specific Features Predict Effective Drugs to Combat Zika Virus Infection. Cell Reports, 2017, 21, 517-532.	6.4	305
7	Transcriptome Profiling Uncovers Potential Common Mechanisms in Fetal Trisomies 18 and 21. OMICS A Journal of Integrative Biology, 2017, 21, 565-570.	2.0	8
8	The pathophysiology and management of xerosis and mouth conditions in patients with trisomy 21. International Medical Review on Down Syndrome, 2017, 21, 46-50.	0.3	0
9	Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation. Scientific Reports, 2017, 7, 14818.	3.3	148
11	Red blood cell metabolism in Down syndrome: hints on metabolic derangements in aging. Blood Advances, 2017, 1, 2776-2780.	5.2	24
12	Is Gravesâ€™ disease a primary immunodeficiency? New immunological perspectives on an endocrine disease. BMC Medicine, 2017, 15, 174.	5.5	22
13	Cellular Stress Associated with Aneuploidy. Developmental Cell, 2018, 44, 420-431.	7.0	149
14	Dendritic spine pathology and thrombospondin-1 deficits in Down syndrome. Free Radical Biology and Medicine, 2018, 114, 10-14.	2.9	34
15	The TRPM2 ion channel contributes to cytokine hyperproduction in a mouse model of Down Syndrome. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 126-132.	3.8	4
16	Exosomal biomarkers in Down syndrome and Alzheimer's disease. Free Radical Biology and Medicine, 2018, 114, 110-121.	2.9	64
17	Slightly deleterious genomic variants and transcriptome perturbations in Down syndrome embryonic selection. Genome Research, 2018, 28, 1-10.	5.5	36
18	Trisomy of a Down Syndrome Critical Region Globally Amplifies Transcription via HMGN1 Overexpression. Cell Reports, 2018, 25, 1898-1911.e5.	6.4	52
19	Trisomy silencing by XIST normalizes Down syndrome cell pathogenesis demonstrated for hematopoietic defects in vitro. Nature Communications, 2018, 9, 5180.	12.8	38

#	ARTICLE	IF	CITATIONS
20	Rapamycin Treatment Ameliorates Age-Related Accumulation of Toxic Metabolic Intermediates in Brains of the Ts65Dn Mouse Model of Down Syndrome and Aging. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 263.	3.4	11
21	Î²-Np63Î± Suppresses TGFÎ²2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas. <i>Cell Reports</i> , 2018, 24, 3224-3236.	6.4	32
22	Interferons and Proinflammatory Cytokines in Pregnancy and Fetal Development. <i>Immunity</i> , 2018, 49, 397-412.	14.3	336
23	Aicardi goutiÃ¨res syndrome is associated with pulmonary hypertension. <i>Molecular Genetics and Metabolism</i> , 2018, 125, 351-358.	1.1	35
24	Integrated Quantitative Transcriptome Maps of Human Trisomy 21 Tissues and Cells. <i>Frontiers in Genetics</i> , 2018, 9, 125.	2.3	38
25	Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. <i>Journal of Leukocyte Biology</i> , 2018, 104, 499-514.	3.3	122
26	Trisomy 21 Represses Cilia Formation and Function. <i>Developmental Cell</i> , 2018, 46, 641-650.e6.	7.0	50
27	Microbiota-Driven Tonic Interferon Signals in Lung Stromal Cells Protect from Influenza Virus Infection. <i>Cell Reports</i> , 2019, 28, 245-256.e4.	6.4	208
28	Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors. <i>Nature Communications</i> , 2019, 10, 4766.	12.8	73
29	Mass Cytometry Reveals Global Immune Remodeling with Multi-lineage Hypersensitivity to Type I Interferon in Down Syndrome. <i>Cell Reports</i> , 2019, 29, 1893-1908.e4.	6.4	78
30	Mechanisms of Leukemia Evolution: Lessons from a Congenital Syndrome. <i>Cancer Cell</i> , 2019, 36, 115-117.	16.8	7
31	Human trisomy 21 fibroblasts rescue methotrexate toxic effect after treatment with 5Ã¢methylnÃ¢tetrahydrofolate and 5Ã¢formylnÃ¢tetrahydrofolate. <i>Journal of Cellular Physiology</i> , 2019, 234, 15010-15024.	4.1	12
32	Downregulated Wnt/Î²-catenin signalling in the Down syndrome hippocampus. <i>Scientific Reports</i> , 2019, 9, 7322.	3.3	20
33	Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata. <i>JAAD Case Reports</i> , 2019, 5, 365-367.	0.8	33
34	Whole genome bisulfite sequencing of Down syndrome brain reveals regional DNA hypermethylation and novel disorder insights. <i>Epigenetics</i> , 2019, 14, 672-684.	2.7	39
35	Diacylglycerol kinase control of protein kinase C. <i>Biochemical Journal</i> , 2019, 476, 1205-1219.	3.7	34
36	Lysosomal Dysfunction in Down Syndrome Is APP-Dependent and Mediated by APP-Î²2CTF (C99). <i>Journal of Neuroscience</i> , 2019, 39, 5255-5268.	3.6	109
37	Primary Immunodeficiency and Cancer Predisposition Revisited: Embedding Two Closely Related Concepts Into an Integrative Conceptual Framework. <i>Frontiers in Immunology</i> , 2018, 9, 3136.	4.8	47

#	ARTICLE	IF	CITATIONS
38	Trisomy 21 Is a Cause of Permanent Neonatal Diabetes That Is Autoimmune but Not HLA Associated. Diabetes, 2019, 68, 1528-1535.	0.6	22
39	Gene and protein expression profiles of JAK-STAT signalling pathway in the developing brain of the Ts1Cje down syndrome mouse model. International Journal of Neuroscience, 2019, 129, 871-881.	1.6	11
40	Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 24231-24241.	7.1	82
41	Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis?. Cells, 2019, 8, 1591.	4.1	18
42	The diverse consequences of aneuploidy. Nature Cell Biology, 2019, 21, 54-62.	10.3	140
43	Placental development and function in trisomy 21 and mouse models of Down syndrome: Clues for studying mechanisms underlying atypical development. Placenta, 2020, 89, 58-66.	1.5	9
44	Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down Syndrome. Trends in Molecular Medicine, 2020, 26, 150-169.	6.7	16
45	mitoXplorer, a visual data mining platform to systematically analyze and visualize mitochondrial expression dynamics and mutations. Nucleic Acids Research, 2020, 48, 605-632.	14.5	47
46	Clinical characteristics of individuals with Down syndrome deceased with COVID-19 in Italy: A case series. American Journal of Medical Genetics, Part A, 2020, 182, 2964-2970.	1.2	17
47	Apigenin as a Candidate Prenatal Treatment for Trisomy 21: Effects in Human Amniocytes and the Ts1Cje Mouse Model. American Journal of Human Genetics, 2020, 107, 911-931.	6.2	16
48	Rescuing Over-activated Microglia Restores Cognitive Performance in Juvenile Animals of the Dp(16) Mouse Model of Down Syndrome. Neuron, 2020, 108, 887-904.e12.	8.1	82
49	Meta-analysis of metabolites involved in bioenergetic pathways reveals a pseudohypoxic state in Down syndrome. Molecular Medicine, 2020, 26, 102.	4.4	21
50	JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome. Cell Reports, 2020, 33, 108407.	6.4	23
51	Mitigating Cognitive Deficits in Down Syndrome by Managing Microglia Activation. Neuron, 2020, 108, 799-800.	8.1	1
52	Bourgeoning Scientific Research in Down Syndrome. Journal of Clinical Immunology, 2020, 40, 789-790.	3.8	0
53	Down syndrome, accelerated aging and immunosenescence. Seminars in Immunopathology, 2020, 42, 635-645.	6.1	35
54	Antiviral Immune Response in Alzheimer's Disease: Connecting the Dots. Frontiers in Neuroscience, 2020, 14, 577744.	2.8	1
55	Cerebellar degeneration-related protein 1 expression in fibroblasts of patients affected by down syndrome. International Journal of Transgender Health, 2020, 13, 548-555.	2.3	0

#	ARTICLE	IF	CITATIONS
56	Autoimmune Thyroid Disease in Specific Genetic Syndromes in Childhood and Adolescence. <i>Frontiers in Endocrinology</i> , 2020, 11, 543.	3.5	51
57	Susceptibility to Heart Defects in Down Syndrome Is Associated with Single Nucleotide Polymorphisms in HAS 21 Interferon Receptor Cluster and VEGFA Genes. <i>Genes</i> , 2020, 11, 1428.	2.4	9
58	Defining behavioral challenges in Down syndrome utilizing a multidimensional dynamic approach: Implications for treatment intervention. <i>International Review of Research in Developmental Disabilities</i> , 2020, , 187-218.	0.8	0
59	Impact of Coronavirus Disease 2019 (COVID-19) on Patients With Congenital Heart Disease Across the Lifespan: The Experience of an Academic Congenital Heart Disease Center in New York City. <i>Journal of the American Heart Association</i> , 2020, 9, e017580.	3.7	46
60	Down Syndrome and COVID-19: A Perfect Storm?. <i>Cell Reports Medicine</i> , 2020, 1, 100019.	6.5	86
61	Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome. <i>Leukemia</i> , 2020, 34, 1984-1999.	7.2	34
62	Cystathionine- β -synthase: Molecular Regulation and Pharmacological Inhibition. <i>Biomolecules</i> , 2020, 10, 697.	4.0	113
63	Three Copies of Four Interferon Receptor Genes Underlie a Mild Type I Interferonopathy in Down Syndrome. <i>Journal of Clinical Immunology</i> , 2020, 40, 807-819.	3.8	44
64	Genetic and epigenetic pathways in Down syndrome: Insights to the brain and immune system from humans and mouse models. <i>Progress in Brain Research</i> , 2020, 251, 1-28.	1.4	13
65	Immune Dysregulation in Children With Down Syndrome. <i>Frontiers in Pediatrics</i> , 2020, 8, 73.	1.9	57
66	Inborn Errors of Adaptive Immunity in Down Syndrome. <i>Journal of Clinical Immunology</i> , 2020, 40, 791-806.	3.8	25
67	Exposure of Patient-Derived Mesenchymal Stromal Cells to TGFB1 Supports Fibrosis Induction in a Pediatric Acute Megakaryoblastic Leukemia Model. <i>Molecular Cancer Research</i> , 2020, 18, 1603-1612.	3.4	1
68	Tumoural soft tissue calcification in Down syndrome: association with heterozygous germline SAMD9 mutation and hyperactive type I interferon signaling. <i>Rheumatology</i> , 2020, 59, e102-e104.	1.9	2
69	Down syndrome. <i>Nature Reviews Disease Primers</i> , 2020, 6, 9.	30.5	376
70	Deep Intronic Mutation in SERPING1 Caused Hereditary Angioedema Through Pseudoexon Activation. <i>Journal of Clinical Immunology</i> , 2020, 40, 435-446.	3.8	20
71	The re-emerging pathophysiological role of the cystathionine- β -synthase α -hydrogen sulfide system in Down syndrome. <i>FEBS Journal</i> , 2020, 287, 3150-3160.	4.7	36
72	Role of 3-Mercaptopyruvate Sulfurtransferase in the Regulation of Proliferation and Cellular Bioenergetics in Human Down Syndrome Fibroblasts. <i>Biomolecules</i> , 2020, 10, 653.	4.0	24
73	Development of IFN-Stimulated Gene Expression from Embryogenesis through Adulthood, with and without Constitutive MDA5 Pathway Activation. <i>Journal of Immunology</i> , 2020, 204, 2791-2807.	0.8	0

#	ARTICLE	IF	CITATIONS
74	Translating JAKs to Jakinibs. <i>Journal of Immunology</i> , 2020, 204, 2011-2020.	0.8	46
75	Pulmonary hypertension in children with Down syndrome. <i>Pediatric Pulmonology</i> , 2021, 56, 621-629.	2.0	29
76	SARS-CoV-2 Triggering Severe Acute Respiratory Distress Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in a 3-Year-Old Child With Down Syndrome. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 543-546.	1.3	11
77	Downâ€™s syndrome and COVID-19: risk or protection factor against infection? A molecular and genetic approach. <i>Neurological Sciences</i> , 2021, 42, 407-413.	1.9	11
78	Down Syndrome patients with COVID-19 pneumonia: A high-risk category for unfavourable outcome. <i>International Journal of Infectious Diseases</i> , 2021, 103, 607-610.	3.3	9
79	Consequences of aneuploidy in human fibroblasts with trisomy 21. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	48
80	JAK inhibition for treatment of psoriatic arthritis in Down syndrome. <i>Rheumatology</i> , 2021, 60, e309-e311.	1.9	12
81	Meta-analysis of gene expression patterns in Down syndrome highlights significant alterations in mitochondrial and bioenergetic pathways. <i>Mitochondrion</i> , 2021, 57, 163-172.	3.4	6
82	Precocious clonal hematopoiesis in Down syndrome is accompanied by immune dysregulation. <i>Blood Advances</i> , 2021, 5, 1791-1796.	5.2	13
83	Seroconversion stages COVID19 into distinct pathophysiological states. <i>ELife</i> , 2021, 10, .	6.0	40
84	Trisomy 21 impairs PGE2 production in dermal fibroblasts. <i>Prostaglandins and Other Lipid Mediators</i> , 2021, 153, 106524.	1.9	1
85	Prenatal histological, cellular, and molecular anomalies in <scp>trisomy</scp> 21 lung. <i>Journal of Pathology</i> , 2021, 255, 41-51.	4.5	10
86	Down syndrome is an oxidative phosphorylation disorder. <i>Redox Biology</i> , 2021, 41, 101871.	9.0	18
87	Expanding the clinical and neuroimaging features of post-varicella arteriopathy of childhood. <i>Journal of Neurology</i> , 2021, 268, 4846-4865.	3.6	6
88	The transcriptome profile of human trisomy 21 blood cells. <i>Human Genomics</i> , 2021, 15, 25.	2.9	13
89	Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 621440.	4.8	26
90	Genetic Susceptibility to Periodontal Disease in Down Syndrome: A Case-Control Study. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6274.	4.1	6
91	Transcriptome and metabolome analysis of crGART, a novel cell model of de novo purine synthesis deficiency: Alterations in CD36 expression and activity. <i>PLoS ONE</i> , 2021, 16, e0247227.	2.5	2

#	ARTICLE	IF	CITATIONS
93	Genotoxic stress in constitutive trisomies induces autophagy and the innate immune response via the cGAS-STING pathway. <i>Communications Biology</i> , 2021, 4, 831.	4.4	22
94	Trisomy 21-associated increases in chromosomal instability are unmasked by comparing isogenic trisomic/disomic leukocytes from people with mosaic Down syndrome. <i>PLoS ONE</i> , 2021, 16, e0254806.	2.5	4
95	Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 700280.	3.4	11
96	Astrocytes in Down Syndrome Across the Lifespan. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 702685.	3.7	19
99	The Mutational Landscape of Myeloid Leukaemia in Down Syndrome. <i>Cancers</i> , 2021, 13, 4144.	3.7	7
100	Atypical Presentation of Systemic Arthritis in a Toddler with Down Syndrome. <i>Case Reports in Pediatrics</i> , 2021, 2021, 1-4.	0.4	2
101	Dermatologic conditions in Down syndrome. <i>Pediatric Dermatology</i> , 2021, 38, 49-57.	0.9	10
102	Functional genomics atlas of synovial fibroblasts defining rheumatoid arthritis heritability. <i>Genome Biology</i> , 2021, 22, 247.	8.8	27
103	Lung disease manifestations in Down Syndrome. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 321, L892-L899.	2.9	11
104	Consequences of mitotic failure “The penalties and the rewards. <i>Seminars in Cell and Developmental Biology</i> , 2021, 117, 149-158.	5.0	6
105	Meta-analysis of transcriptomic data reveals clusters of consistently deregulated gene and disease ontologies in Down syndrome. <i>PLoS Computational Biology</i> , 2021, 17, e1009317.	3.2	13
106	The Impact of Ageing on the CNS Immune Response in Alzheimer’s Disease. <i>Frontiers in Immunology</i> , 2021, 12, 738511.	4.8	11
107	Neurodevelopmental Disorders (NDD) Caused by Genomic Alterations of the Ubiquitin-Proteasome System (UPS): the Possible Contribution of Immune Dysregulation to Disease Pathogenesis. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 733012.	2.9	15
108	Innate Immune System Activation and Neuroinflammation in Down Syndrome and Neurodegeneration: Therapeutic Targets or Partners?. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 718426.	3.4	17
109	Down syndrome and type I interferon: not so simple. <i>Current Opinion in Immunology</i> , 2021, 72, 196-205.	5.5	19
110	Increased risk of leukaemia in children with Down syndrome: a somatic evolutionary view. <i>Expert Reviews in Molecular Medicine</i> , 2021, 23, e5.	3.9	3
111	Network analysis of Down syndrome and SARS-CoV-2 identifies risk and protective factors for COVID-19. <i>Scientific Reports</i> , 2021, 11, 1930.	3.3	35
117	IFITM proteins inhibit placental syncytiotrophoblast formation and promote fetal demise. <i>Science</i> , 2019, 365, 176-180.	12.6	111

#	ARTICLE	IF	CITATIONS
118	Transcriptome analysis of genetically matched human induced pluripotent stem cells disomic or trisomic for chromosome 21. PLoS ONE, 2018, 13, e0194581.	2.5	31
119	Signaling a link between interferon and the traits of Down syndrome. ELife, 2016, 5, .	6.0	6
121	Interferon-Driven Immune Dysregulation in Down Syndrome: A Review of the Evidence. Journal of Inflammation Research, 2021, Volume 14, 5187-5200.	3.5	15
130	Prevalence of pulmonary hypertension among children with Down syndrome: A systematic review and meta-analysis. World Journal of Clinical Pediatrics, 2021, 10, 177-191.	2.1	2
131	BDdb: a comprehensive platform for exploration and utilization of birth defect multi-omics data. BMC Medical Genomics, 2021, 14, 260.	1.5	1
132	Stankiewicz-Isidor syndrome: expanding the clinical and molecular phenotype. Genetics in Medicine, 2022, 24, 179-191.	2.4	9
133	Prenatal and Postnatal Pharmacotherapy in Down Syndrome: The Search to Prevent or Ameliorate Neurodevelopmental and Neurodegenerative Disorders. Annual Review of Pharmacology and Toxicology, 2022, 62, 211-233.	9.4	7
134	Effects of aneuploidy on cell behaviour and function. Nature Reviews Molecular Cell Biology, 2022, 23, 250-265.	37.0	35
135	Deep immune phenotyping reveals similarities between aging, Down syndrome, and autoimmunity. Science Translational Medicine, 2022, 14, eabi4888.	12.4	20
136	Pulmonary Hypertension in the Population with Down Syndrome. Cardiology and Therapy, 2022, 11, 33-47.	2.6	11
137	Sonic Hedgehog Pathway Modulation Normalizes Expression of Olig2 in Rostrally Patterned NPCs With Trisomy 21. Frontiers in Cellular Neuroscience, 2021, 15, 794675.	3.7	12
140	Down Syndrome-Associated Arthritis (DA): Diagnostic and Management Challenges. Pediatric Health, Medicine and Therapeutics, 2022, Volume 13, 53-62.	1.6	8
141	Integrated Quantitative Neuro-Transcriptome Analysis of Several Brain Areas in Human Trisomy 21. Genes, 2022, 13, 628.	2.4	0
142	The innate immune system stimulating cytokine GM-CSF improves learning/memory and interneuron and astrocyte brain pathology in Dp16 Down syndrome mice and improves learning/memory in wild-type mice. Neurobiology of Disease, 2022, 168, 105694.	4.4	11
144	SOMAmer reagents and the SomaScan platform: Chemically modified aptamers and their applications in therapeutics, diagnostics, and proteomics. , 2022, , 171-260.		6
145	The Conundrum of Lung Disease and Drug Hypersensitivity-like Reactions in Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2022, 74, 1122-1131.	5.6	24
161	Proteostasis Perturbations and Their Roles in Causing Sterile Inflammation and Autoinflammatory Diseases. Cells, 2022, 11, 1422.	4.1	6
162	The Challenging Pathway of Treatment for Neurogenesis Impairment in Down Syndrome: Achievements and Perspectives. Frontiers in Cellular Neuroscience, 2022, 16, .	3.7	6

#	ARTICLE	IF	CITATIONS
163	Clonal hematopoiesis: Mutation-specific adaptation to environmental change. <i>Cell Stem Cell</i> , 2022, 29, 882-904.	11.1	34
164	Evidence of neuroinflammation and immunotherapy responsiveness in individuals with down syndrome regression disorder. <i>Journal of Neurodevelopmental Disorders</i> , 2022, 14, .	3.1	21
166	Biochemical Discrimination of the Down Syndrome-Related Metabolic and Oxidative/Nitrosative Stress Alterations from the Physiologic Age-Related Changes through the Targeted Metabolomic Analysis of Serum. <i>Antioxidants</i> , 2022, 11, 1208.	5.1	1
167	Lamivudine, a reverse transcriptase inhibitor, rescues cognitive deficits in a mouse model of down syndrome. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 4210-4215.	3.6	9
168	Dissecting stepwise mutational impairment of megakaryopoiesis in a model of Down syndrome-associated leukemia. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	1
169	Chromosome instability and aneuploidy as context-dependent activators or inhibitors of antitumor immunity. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
170	Type-I-interferon signaling drives microglial dysfunction and senescence in human iPSC models of Down syndrome and Alzheimer's disease. <i>Cell Stem Cell</i> , 2022, 29, 1135-1153.e8.	11.1	45
171	Treatment of Down Syndrome-Associated Arthritis with JAK Inhibition. <i>Case Reports in Rheumatology</i> , 2022, 2022, 1-3.	0.6	2
172	Adults with Trisomy 21 Have Differential Antibody Responses to Influenza A. <i>Vaccines</i> , 2022, 10, 1145.	4.4	0
173	Chromosome silencing in vitro reveals trisomy 21 causes cell-autonomous deficits in angiogenesis and early dysregulation in Notch signaling. <i>Cell Reports</i> , 2022, 40, 111174.	6.4	5
174	Gene-dosage imbalance due to trisomic HSA21 and genotype-phenotype association in Down syndrome. , 2022, , 93-134.		0
175	Blood counts in children with Down syndrome. <i>Pediatric Blood and Cancer</i> , 0, , .	1.5	0
178	Elitist random swapped particle swarm optimization embedded with variable k-nearest neighbour classification: a new PSO variant applied to gene identification. <i>Soft Computing</i> , 0, , .	3.6	0
179	Biphasic cell cycle defect causes impaired neurogenesis in down syndrome. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	3
180	Excessive negative regulation of type I interferon disrupts viral control in individuals with Down syndrome. <i>Immunity</i> , 2022, 55, 2074-2084.e5.	14.3	15
181	Innovating Therapies for Down Syndrome: An International Virtual Conference of the T21 Research Society. <i>Molecular Syndromology</i> , 2023, 14, 89-100.	0.8	0
182	Hemophagocytic lymphohistocytosis in trisomy 21: successful treatment with interferon inhibition. <i>Pediatric Rheumatology</i> , 2022, 20, .	2.1	1
183	Glial interference: impact of type I interferon in neurodegenerative diseases. <i>Molecular Neurodegeneration</i> , 2022, 17, .	10.8	4

#	ARTICLE	IF	CITATIONS
184	Lung Involvement in Systemic Juvenile Idiopathic Arthritis: A Narrative Review. <i>Diagnostics</i> , 2022, 12, 3095.	2.6	4
185	Consequences of chromosome gain: A new view on trisomy syndromes. <i>American Journal of Human Genetics</i> , 2022, 109, 2126-2140.	6.2	10
186	Consequences of trisomy syndromes “21 and beyond. <i>Trends in Genetics</i> , 2023, 39, 172-174.	6.7	3
187	FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders. <i>Pharmaceuticals</i> , 2022, 15, 1546.	3.8	3
188	Dysregulated systemic metabolism in a Down syndrome mouse model. <i>Molecular Metabolism</i> , 2023, 68, 101666.	6.5	6
189	IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome. <i>Cell Reports</i> , 2022, 41, 111883.	6.4	11
190	State-of-the-art therapy for Down syndrome. <i>Developmental Medicine and Child Neurology</i> , 2023, 65, 870-884.	2.1	4
191	Polymorphic rupioid psoriasis with chamomile-like lesions: A case report. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2023, 37, .	2.4	0
193	Marburg and Ebola Virus Infections Elicit a Complex, Muted Inflammatory State in Bats. <i>Viruses</i> , 2023, 15, 350.	3.3	4
194	Autoimmunity in Down’s syndrome via cytokines, CD4 T cells and CD11c+ B cells. <i>Nature</i> , 2023, 615, 305-314.	27.8	23
195	Keratotic Papules on a Patient With Down Syndrome. <i>American Journal of Dermatopathology</i> , 2023, 45, 145-146.	0.6	0
197	Breaking down the cellular responses to type I interferon neurotoxicity in the brain. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	10
198	The human inactive X chromosome modulates expression of the active X chromosome. <i>Cell Genomics</i> , 2023, 3, 100259.	6.5	20
200	Adverse childhood experiences and the development of <scp>Down</scp> syndrome regression disorder. <i>American Journal of Medical Genetics, Part A</i> , 2023, 191, 1769-1782.	1.2	1
201	Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway. <i>Cancer Research</i> , 2023, 83, 2543-2556.	0.9	2
202	PSMC3 proteasome subunit variants are associated with neurodevelopmental delay and type I interferon production. <i>Science Translational Medicine</i> , 2023, 15, .	12.4	9
203	Genes with immune functions modulate key traits associated with Down syndrome in mice. <i>Nature Genetics</i> , 2023, 55, 910-911.	21.4	0
204	Triplication of the interferon receptor locus contributes to hallmarks of Down syndrome in a mouse model. <i>Nature Genetics</i> , 2023, 55, 1034-1047.	21.4	12

#	ARTICLE	IF	CITATIONS
205	Interferon hyperactivity impairs cardiogenesis in Down syndrome via downregulation of canonical Wnt signaling. <i>IScience</i> , 2023, 26, 107012.	4.1	3
206	Biological and <scp>JAK</scp> inhibitor therapy outcomes for severe psoriasis in trisomy 21. <i>Journal of Dermatology</i> , 0, , .	1.2	0
208	Down syndrome: insights into autoimmune mechanisms. <i>Nature Reviews Rheumatology</i> , 2023, 19, 401-402.	8.0	3
209	From neurodevelopment to neurodegeneration: utilizing human stem cell models to gain insight into Down syndrome. <i>Frontiers in Genetics</i> , 0, 14, .	2.3	0
210	Multidimensional definition of the interferonopathy of Down syndrome and its response to JAK inhibition. <i>Science Advances</i> , 2023, 9, .	10.3	1
212	Down syndrome is associated with altered frequency and functioning of tracheal multiciliated cells, and response to influenza virus infection. <i>IScience</i> , 2023, 26, 107361.	4.1	0
213	Single-cell landscape analysis reveals systematic senescence in mammalian Down syndrome. <i>Clinical and Translational Medicine</i> , 2023, 13, .	4.0	2
214	Single-nucleus profiling identifies accelerated oligodendrocyte precursor cell senescence in a mouse model of Down Syndrome. <i>ENeuro</i> , 0, , ENEURO.0147-23.2023.	1.9	0
215	Bio-Metal Dyshomeostasis-Associated Acceleration of Aging and Cognitive Decline in Down Syndrome. <i>Biological and Pharmaceutical Bulletin</i> , 2023, 46, 1169-1175.	1.4	0
216	Lung and Heart Biology of the Dp16 Mouse Model of down Syndrome: Implications for Studying Cardiopulmonary Disease. <i>Genes</i> , 2023, 14, 1819.	2.4	1
217	Transcriptomic analysis of stem cells from chorionic villi uncovers the impact of chromosomes 2, 6 and 22 in the clinical manifestations of Down syndrome. <i>Stem Cell Research and Therapy</i> , 2023, 14, .	5.5	1
218	Consequences of gaining an extra chromosome. <i>Chromosome Research</i> , 2023, 31, .	2.2	3
219	How to Build a Fire: The Genetics of Autoinflammatory Diseases. <i>Annual Review of Genetics</i> , 2023, 57, .	7.6	0
223	Inhibition of the proline metabolism rate-limiting enzyme P5CS allows proliferation of glutamine-restricted cancer cells. <i>Nature Metabolism</i> , 2023, 5, 2131-2147.	11.9	2
224	Increased lethality of respiratory infection by <i>Streptococcus pneumoniae</i> in the Dp16 mouse model of Down syndrome. <i>FASEB BioAdvances</i> , 2023, 5, 528-540.	2.4	0
225	Down syndrome and leukemia: An insight into the disease biology and current treatment options. <i>Blood Reviews</i> , 2023, , 101154.	5.7	0
227	The immune system in Down Syndrome: Autoimmunity and severe infections. <i>Immunological Reviews</i> , 0, , .	6.0	0
228	Transcriptome research of human amniocytes identifies hub genes associated with developmental dysplasia in down syndrome. <i>Aging</i> , 0, , .	3.1	0

#	ARTICLE	IF	CITATIONS
229	Unraveling Down Syndrome: From Genetic Anomaly to Artificial Intelligence-Enhanced Diagnosis. Biomedicines, 2023, 11, 3284.	3.2	2
230	Partial loss of Sorting Nexin 27 resembles age- and Down syndrome-associated T cell dysfunctions. Immunity and Ageing, 2024, 21, .	4.2	0
231	Safety and tolerability of intravenous immunoglobulin infusion in Down syndrome regression disorder. American Journal of Medical Genetics, Part A, 2024, 194, .	1.2	0
232	Inherent genome instability underlies trisomy 21-associated myeloid malignancies. Leukemia, 2024, 38, 521-529.	7.2	0
233	Increased dosage of DYRK1A leads to congenital heart defects in a mouse model of Down syndrome. Science Translational Medicine, 2024, 16, .	12.4	1
234	Down Syndrome Biobank Consortium: A perspective. Alzheimer's and Dementia, 2024, 20, 2262-2272.	0.8	1
235	Altered peripheral blood leukocyte subpopulations, function, and gene expression in children with Down syndrome: implications for respiratory tract infection. European Journal of Medical Genetics, 2024, 68, 104922.	1.3	0
236	Antileukemic effect of azacitidine, a DNA methyltransferase inhibitor, on cell lines of myeloid leukemia associated with Down syndrome. Experimental Hematology, 2024, 132, 104179.	0.4	0
237	SARS-CoV-2 Infection Causes Heightened Disease Severity and Mortality in a Mouse Model of Down Syndrome. Biomedicines, 2024, 12, 543.	3.2	0
238	Nucleotide metabolism, leukodystrophies, and <scp>CNS</scp> pathology. Journal of Inherited Metabolic Disease, 0, , .	3.6	0